FDG-PET for detecting local tumor recurrence of ablated liver metastases: a diagnostic meta-analysis.
BACKGROUND
Scanty reports have focused on FDG-PET after radiofrequency ablation (RFA), for recurrence of hepatic metastases.


OBJECTIVE
To assess FDG-PET diagnostic accuracy on detection of recurrent hepatic lesions.


METHODS
After a comprehensive search of PubMed and EMBASE, we performed a patient-based diagnostic meta-analysis of post-RFA FDG-PET.


RESULTS
Across nine included articles, independent, random-effects sensitivity and specificity were 0.73(0.50-0.88) and 0.85(0.72-0.93), respectively. A symmetrical SROC curve was produced with no significant heterogeneity. Specificity was optimal for surgical RFA and colorectal origin of metastases.


CONCLUSIONS
Synthesis of published evidence suggests PET/CT as an appropriate tool for optimizing post-ablation follow-up.
Department of Medical Imaging and Interventional Radiology, General Hospital of Chest Diseases "Sotiria", Athens, Greece. ploukia@hotmail.com
Loukia S
LS
Poulou
Panayiotis D
PD
Ziakas
Dimitrios C
DC
Ziogas
Chrysoula
C
Doxani
Vassilia
V
Xyla
George
G
Vakrinos
Michael
M
Voulgarelis
Loukas
L
Thanos
D019540:Area Under Curve; D017115:Catheter Ablation; D015179:Colorectal Neoplasms / Q000000981:diagnostic imaging / Q000473:pathology / Q000601:surgery*; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008113:Liver Neoplasms / Q000000981:diagnostic imaging / Q000556:secondary / Q000601:surgery*; D064847:Multimodal Imaging; D009364:Neoplasm Recurrence, Local / Q000000981:diagnostic imaging* / Q000517:prevention & control; D049268:Positron-Emission Tomography; D012372:ROC Curve; D019275:Radiopharmaceuticals; D016634:Radiosurgery; D014057:Tomography, X-Ray Computed
D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18